Updates in Atopic Dermatitis Logo

Updates in Atopic Dermatitis: The Allergist's Guide to Optimizing Care

The prevalence of atopic dermatitis (AD) in industrialized nations is estimated at up to 30% for children and up to 10% for adults. The vast majority (85%) of affected patients develop symptoms before reaching their 5th birthday. For children, severity can increase with age, although in 70% of childhood cases AD remits by adolescence.

The cardinal symptom of AD is pruritus, which can begin a vicious cycle entailing subsequent increased inflammation, excoriation, further itching and scratching, and increased risk for infection. Many cases are classified as mild; however moderate-to-severe cases (which can affect up to about a third of patients present a particular challenge.

To clarify these challenges, the American Academy of Allergy, Asthma & Immunology (AAAAI) and The France Foundation (TFF) have designed a certified medical education initiative through which non-dermatology specialists can increase their knowledge, confidence and competence in the diagnosis, assessment and treatment of patients with AD.

This initiative includes 2 highly interactive, on-demand activities:

  • Diagnosis and Management in Adults
  • Diagnosis and Management in Infants and Children

Updates in Atopic Dermatitis is supported by an educational grant from Pfizer.


The following is a link to the abstract of a companion article printed in the Journal of Clinical Allergy: In Practice:

Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection


 

Target Audience

  • Allergist/immunologists
  • Fellows-in-Training
  • Nurses and Nurse Practitioners
  • Physician Assistants and Other Allied Health Professionals

Learning Objectives

Upon completion of the activity, participants should be able to:

  • Diagnose AD chiefly on the basis of the clinical exam
  • Evaluate severity on the basis of provided criteria and evaluation tools, as appropriate
  • Address exacerbations appropriately, on the basis of evidence and recommendations
  • Select treatment for moderate-to-severe AD on the basis of available data
Summary
Course opens: 
05/01/2019
Course expires: 
05/31/2021
Cost:
$0.00
Rating: 
5
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AAAAI and The France Foundation. The AAAAI is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement 

The American Academy of Allergy, Asthma & Immunology designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Designation Statement

The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 1.00 Contact Hours.

Credit Claiming Period

Credit claiming for this activity will expire at 11:59 pm on Month Day, Year. Requests to claim credit on or after Month Day, Year will be denied.

AAAAI Privacy Policy

To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

Questions

Activity-related questions should be directed to  cme@aaaai.org.

Available Credit

Accreditation Period

Course opens: 
05/01/2019
Course expires: 
05/31/2021
 
Status
Price
Activity Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari.

Internet Explorer is no longer supported.